ArticleFrontiers in public health2023
Strengthening pathogen genomic surveillance for health emergencies: insights from the World Health Organization's regional initiatives.
Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Lassa virus live tracking and lineage assignment: how nextstrain can enhance surveillance and public health in Africa and beyond.Emerging microbes & infections · 2026Article
- Improving public health laboratory preparedness at European Union level: learning points from experiences during the COVID-19 pandemic.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Review
- Advancing genomics for waterborne pathogen surveillance in Australia.The Lancet regional health. Western Pacific · 2026Review
- Mapping pathogen genomics training provision: a structured analysis within a global consortium network.Frontiers in public health · 2026Article
- Phylogenetic insights into the transmission dynamics of arthropod-borne viruses.Nature reviews. Genetics · 2026Review
- Next-generation sequencing and bioinformatics capacity: findings from a multi-country survey to guide the genomics costing tool 2.0.Frontiers in public health · 2026Article
- Genomics in Epidemiology and Disease Surveillance: An Exploratory Analysis.Life (Basel, Switzerland) · 2025Review
- [Overview of PCR-based Diagnostic Assays for Emerging Infectious Disease Pathogens].Jugan geon-gang gwa jilbyeong · 2025Review
- CLASV: Rapid Lassa virus lineage assignment with random forest.PLoS neglected tropical diseases · 2025Article
- The Microbiological Characteristics and Genomic Surveillance of Carbapenem-ResistantMicroorganisms · 2025Article
- Reducing Supply Chain Dependencies for Viral Genomic Surveillance: Get by with a Little HELP from Commercial Enzymes already in your Lab Freezer.Wellcome open research · 2025Article
- A capacity strengthening model toward self-reliant and sustainable one-health workforce in six East African Community Partner States.Frontiers in public health · 2025Article
- A rapid evaluation of the UK Health Security Agency's New Variant Assessment Platform global genomic surveillance programme.PLOS global public health · 2025Article
- Genomics and Bioinformatics in One Health: Transdisciplinary Approaches for Health Promotion and Disease Prevention.International journal of environmental research and public health · 2024Article
- Detection and Characterisation of SARS-CoV-2 in Eastern Province of Zambia: A Retrospective Genomic Surveillance Study.International journal of molecular sciences · 2024Article
- Assessment of the pathogen genomics landscape highlights disparities and challenges for effective AMR Surveillance and outbreak response in the East African community.BMC public health · 2024Article
- Genomic surveillance of SARS-CoV-2 in North Africa: 4 years of GISAID data sharing.IJID regions · 2024Article
- Empowering public health: building advanced molecular surveillance in resource-limited settings through collaboration and capacity-building.Frontiers in health services · 2024Article
- Investing in health preparedness, response and resilience: a genomics costing tool focused on next generation sequencing.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
Abstract
The onset of the COVID-19 pandemic triggered a rapid scale-up in the use of genomic surveillance as a pandemic preparedness and response tool. As a result, the number of countries with in-country SARS-CoV-2 genomic sequencing capability increased by 40% from February 2021 to July 2022. The Global Genomic Surveillance Strategy for Pathogens with Pandemic and Epidemic Potential 2022-2032 was launched by the World Health Organization (WHO) in March 2022 to bring greater coherence to ongoing work to strengthen genomic surveillance. This paper describes how WHO's tailored regional approaches contribute to expanding and further institutionalizing the use of genomic surveillance to guide pandemic preparedness and response measures as part of a harmonized global undertaking. Challenges to achieving this vision include difficulties obtaining sequencing equipment and supplies, shortages of skilled staff, and obstacles to maximizing the utility of genomic data to inform risk assessment and public health action. WHO is helping to overcome these challenges in collaboration with partners. Through its global headquarters, six regional offices, and 153 country offices, WHO is providing support for country-driven efforts to strengthen genomic surveillance in its 194 Member States, with activities reflecting regional specificities. WHO's regional offices serve as platforms for those countries in their respective regions to share resources and knowledge, engage stakeholders in ways that reflect national and regional priorities, and develop regionally aligned approaches to implementing and sustaining genomic surveillance within public health systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.